visceral adiposity comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-14. Numbers and descriptions here follow the published literature rather than marketing material.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
=== Darlene Conner-Olinsky === Darlene Conner-Olinsky is played by Sara Gilbert. She is Dan and Roseanne's second child and younger daughter, born in 1977. Darlene, who has inherited her mother's acerbic sense of humor, is artistic, tomboyish, and socially awkward. In the early seasons, Darlene mostly focuses on sports and, though highly intelligent, underperforms academically. She often mocks her older sister Becky for being a model student, her feminine pursuits, and for chasing boys. As a teenager, Darlene grows increasingly moody and withdrawn, her malaise gradually leading to a brief bout of depression. She is a strong animal rights activist and becomes a vegetarian, which closely reflects Gilbert's real-life views. In middle school, Darlene is generally uninterested in boys though she has a few dates. As a high school freshman, she begins dating David Healy (called Kevin Healy in his first appearance, though the name was changed). David (Johnny Galecki) is the younger brother of Becky's punk boyfriend (later husband) Mark. Darlene is sarcastic and domineering like her mother, often causing the two to clash. Her strong personality dominates the meek David, who usually defers to her. Darlene is a talented aspiring writer and David is a budding graphic artist, leading them to collaborate on a graphic novel. Darlene's goal is to become a professional writer and is talented enough to be awarded early admission and a scholarship to an arts college in Chicago. After David's application to the same school is declined, he wants Darlene to remain in Lanford.
He also helped fund much research, through the iron foundry which he owned and directed. His statue is prominently placed in front of the Gallery of Evolution. Following the French Revolution the MNHN was reorganised, with twelve professorships of equal rank. Some of its early professors included eminent comparative anatomist Georges Cuvier and the pioneers of the theory of evolution, Jean-Baptiste de Lamarck and Étienne Geoffroy Saint-Hilaire. The museum's aims were to instruct the public, put together collections and conduct scientific research. The naturalist Louis Jean Marie Daubenton wrote extensively about biology for the pioneer French Encyclopédie, and gave his name to several newly discovered species. The museum sent its trained botanists on scientific expeditions around the world. Major figures in the MNHN included Déodat de Dolomieu, who gave his name to the mineral dolomite and to a volcano on Réunion island, and the botanist Rene Desfontaines, who spent two years collecting plants for study Tunisia and Algeria, and whose book "Flora Atlantica" (1798–1799, 2 vols), added three hundred genera new to science. When Napoleon Bonaparte launched his military campaign to conquer Egypt in 1798, his army was accompanied by more than 154 scientists, including botanists, chemists, mineralogists, including Étienne Geoffroy Saint-Hilaire, Vivant Denon, Joseph Fourier, and Claude Louis Berthollet, who together took back a large quantity of specimens and illustrations to enrich the collections of the museum.
Degradation of an amino acid often begins with transamination, in which its amino group is transferred to α-ketoglutarate, forming glutamate. This process involves transaminases, often the same enzymes used in amino acid synthesis. In many vertebrates, the amino group is subsequently released as ammonia and converted to urea via the urea cycle for excretion. However, amino acid degradation can result in uric acid or ammonia instead, depending on the organism. For example, serine dehydratase converts serine directly to pyruvate and ammonia. After removal of one or more amino groups, the remaining carbon skeleton of an amino acid can serve as a precursor for synthesizing other amino acids, be further metabolized for energy after conversion into intermediates of glycolysis (typically via gluconeogenesis) or of the citric acid cycle, or be used for fatty acid synthesis and storage as triacylglycerol. Amino acids are bidentate ligands, forming transition metal amino acid complexes.
Myasthenia gravis Acute intoxication with alcohol, narcotics, or other psychoactive substances Ataxia Severe hypoventilation Acute narrow-angle glaucoma Severe liver deficiencies (hepatitis and liver cirrhosis decrease elimination by a factor of 2) Severe sleep apnea Hypersensitivity or allergy to any drug in the benzodiazepine class Chlordiazepoxide is generally considered an inappropriate benzodiazepine for the elderly due to its long elimination half-life and the risks of accumulation. Benzodiazepines require special precaution if used in the elderly, pregnancy, children, alcohol- or drug-dependent individuals and individuals with comorbid psychiatric disorders.
=== Energy intake === 5-HT2C receptor agonists reduce appetite by working on serotonin receptors in a region of the brain called the hypothalamus. Lorcaserin (Belviq) was FDA approved for weight loss but was withdrawn from the market because a safety clinical trial shows an increased occurrence of cancer. Cannabinoid receptor antagonists were developed to treat obesity because researchers noticed that cannabinoid agonists (such as THC, the main pharmacologically active component of cannabis), increased appetite. However, some drugs in this class such as rimonabant were withdrawn or ceased development due to concerns about mental health and suicide. More selective drugs—some are in development that act only in peripheral tissues, not the brain—may be able to achieve this result with fewer adverse effects. GLP-1 agonists such as tirzepatide, semaglutide, and liraglutide slow gastric emptying and also have neurologically driven effects on appetite. It is unknown if GLP-1 agonists or dual/triple agonists of GLP-1 and/or the glucagon or GIP receptors act solely by reducing energy intake or if they also increase energy expenditure. Setmelanotide is an agonist of the melanocortin 4 receptor and is used in people with certain rare genetic conditions that cause obesity. It is less effective and not approved for general obesity.
Sources: en.wikipedia.org
== Narcotics corruption == Drug-related corruption reportedly began to take a firm hold within Bolivia's military and security services under General Banzer's rule (1971–78). In 1980 the Junta of Commanders headed by Luis García Meza Tejada forced a violent coup d'etat—sometimes referred to as the Cocaine Coup - on 17 July. The García Meza regime (1980–81) was one of Bolivia's most flagrant examples of narcotics corruption. García Meza's so-called cocaine coup was itself generally believed to have been financed by the cocaine "mafia," which bribed certain military officers. García Meza reportedly ruled with an "inner cabinet" of leading civilians and military officers involved in the cocaine trade. Two of his ministers—Colonel Ariel Coca and Colonel Luis Arce Gómez—were well-known "godfathers" of the industry. By 1982 approximately 4,500 prosecutions were under way in connection with the embezzlement of state funds by civil servants, said to amount to a total of US$100 million. Garcia Meza's rule was so violent, and his regime so internationally isolated due to his drug trafficking, that he was forced to resign in 1981. His main collaborator, Colonel Luis Arce Gómez, was extradited to the United States, where he served a jail sentence for drug trafficking. In early 1986, Congress charged García Meza and fifty-five of his former colleagues with sedition, armed uprising, treason, genocide, murder, torture, fraud against the state, drug trafficking, crimes against the Constitution, and other crimes.
== Signs and symptoms == How myiasis affects the human body depends on where the larvae are located. Larvae may infect dead, necrotic (prematurely dying) or living tissue in various sites: the skin, eyes, ears, stomach, and intestinal tract, or in genitourinary sites. They may invade open wounds and lesions or unbroken skin. Some enter the body through the nose or ears. Larvae or eggs can reach the stomach or intestines if they are swallowed with food and cause gastric or intestinal myiasis. In extremely rare cases, maggots may occasionally infest the vulvar area. Several different presentations of myiasis and their symptoms:
=== Three dimensional artifacts === Three-dimensional artifacts that have been damaged often require Full backings, but are difficult to apply to three-dimensional textiles. Tailoring techniques such as darts, gathering, similar to original construction techniques can be employed to create shaped backings or supports Occasionally, disassembly is permitted for three-dimensional materials. Shaped forms are also sometimes used as supports. When textiles are used in three-dimensional structures such as covered boxes and upholstered furniture are damaged an overlay can be stitched into lower layers. A less invasive treatment option is passive support. Conditions for use of passive supports: - no major structural damages (tears or holes) - The ground fabric must be intact. - Ideally the textile on its original strainer. - Requires protection against puncture. - Supplementary supports help in limit damages as a result of vibration, shock, and flexing. - The fabric requires additional protection because it is sagging on the strainer. - In the event that the textile has never been removed from its original strainer. The below techniques must be modified to accommodate original lacing: A padded insert provides passive protection. A padded, fabric-covered insert should be created specifically for the object to fill the strainer. Polyester felt or batting can be utilized for a precise fit. A rigid backing (archival-quality rag board of appropriate thickness/rigidity), should be affixed to the insert by thread ties, sewing, or adhesives is used to keep the padded insert secure.
=== Former all-vegetarian locations === Alcott House in Surrey, United Kingdom Ephrata Cloister in Pennsylvania, United States Fruitlands in Massachusetts, United States Octagon City, Kansas, United States The Sanctuary (community) in West Sussex, United Kingdom
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.